Modified Form PTO-1449		Atty. Docket No.		Serial No.	
			A-579B		09/890,729
LIST OF REFERENCES CITED BY APPLICANT		Applicant			
(Use several sheets if necessary)			Yoshinaga, et al		
		Filing Date		Group	
			January 27, 2000		1644

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-	TRANSLATION

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Attwood, T., "The Babel of Bioinformatics", *Science*, 290: 471-473, (20 Oct 2000).
	C2	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", *Science*, 247: 1306-1310, (16 March 1990).
	C3	Dai, Z. et al., "The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection", *Current Opinion in Immunology* 1999 United Kingdom, Vol. 11, No. 5, 504-508,(1999).
	C4	Database EMBL [Online] "Homo sapiens mRNA for KIAA0653 protein, partial cds." EBI Accession No. AB014553, 15 July 1998.
	C5	Database EMBL [Online] "yg34c12.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:34465 5', mRNA sequence." EBI Assession No. R23544, 23 April 1995.
	C6	Database UNIPROT [Online] Wang, et al.: "ICOS ligand precursor (B7 homolog 2) (B7-H2) (B7-like protein G150) (B7-related protein 1) (B7RP-1) (CD275 antigen)", UNIPROT Assession No. 075144, 15 July 1999.
	C7	Database UNIPROT [Online] O'Regan, et al., "ICOS ligand", UNIPROT Assession No. 042404, 1 January 1998.
	C8	Database EMBL [Online] "vg32f09.r1 Soares mouse mammary glad NbMMG Mus musculus cDNA clone IMAGE:863081 5', mRNA sequence.", EMBL Assession No. AA510455, 9 July 1997.
	C9	Fick, R. B., et al., "Immunotherapy approach to allergic disease", *Immunopharmacology*, 48: 307-310, (25 July 2000).
	C10	Heaney, Liam G., et al., "Severe asthma treatment: need for characterising patients", *Lancet*, 365: 974-976, (12 March 2005).

EXAMINER:	Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

Modified Form PTO-1449		Atty. Docket No. A-579B	Serial No. 09/890,729
LIST OF REFERENCES CITED BY APPLICANT		Applicant Yoshinaga, et al	
(Use several sheets if necessary)		Filing Date January 27, 2000	Group 1644

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C11	Huang, Ziwei, "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis", *Pharmacology & Therapeutics*, 86: 201-215, (2000).
	C12	Ishikawa, et al., "Prediction of the coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteins *in vitro*', *DNA Rsh.*, 5: 169-176 (1998)
	C13	Kahan, Barry D., Immunosuppressive therapy", *Current Opinion in Immunology*, 4: 553-559, (1992).
	C14	Metzler, et al., Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28", *Nature Structural Biology*, 4, No. 7: 527-531, (July 1997).
	C15	The Merck Manual of Diagnosis and Therapy, Section 6 – Pulmonary Disorders, Chapter 68, Seventeenth Edition, Published by Merck Research Laboratories, Division of Merck & Co., Inc., Whitehouse Station, NJ, 556-557, (1999).
	C16	Schultze, J., et al., "B7-mediated costimulation and the immune response", *Blood Reviews 1996 United Kingdom*, 10, No. 2, 111-127, (1996).
	C17	Skolnick, Jeffrey, et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", *Trends in Biotechnology*, 18(1): 34-39, (January 2000).

EXAMINER: /Ilia Ouspenski/	Date Considered: 04/09/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./